MedTrace Logo

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

NCT03094663 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

A comparison of two pain control methods - the combination of Adductor Canal Block (ACB)/Periarticular Injection (PAI)/Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (IPACK) versus the Periarticular Injection (PAI) - in patients undergoing total knee arthroplasty. Primary outcome is NRS pain scores with ambulation on postoperative day one (24 hours post-block administration).

Conditions

  • Knee Arthropathy

Interventions

DRUG

Bupivacaine with epinephrine

bupivacaine 0.5% with epinephrine 30cc

DRUG

Methylprednisolone

40 mg/ml, 1 ml

DRUG

Cefazolin

500 mg in 10 ml

DEVICE

8 MHz. Chiba needle

22G/ 4 inches

DRUG

Bupivacaine with Dexamethasone

15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone

DRUG

Bupivacaine 25cc

25 cc 0.25% bupivacaine

DRUG

Bupivacaine 20cc

20cc 0.25% bupivacaine

DRUG

Dexamethasone

2 mg IV dexamethasone.

Sponsors & Collaborators

  • Hospital for Special Surgery, New York

    lead OTHER

Principal Investigators

  • David H Kim, MD · Hospital for Special Surgery, New York

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2018-05-31
Completion
2018-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03094663 on ClinicalTrials.gov